CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Palisade Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Palisade Bio Inc
7750 El Camino Real, Suite 5200
Phone: (858) 704-4900p:858 704-4900 CARLSBAD, CA  92009  United States Ticker: PALIPALI
Business Summary
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Donald A.Williams 63 2/9/2024 4/27/2021
Chief Executive Officer, Chief Financial Officer, Director J. D.Finley 65 6/1/2023 4/1/2021
Chief Operating Officer RobertMcrae 39 2/2/2023 2/2/2023
Chief Medical Officer MitchellJones 45 9/5/2023 9/5/2023
Independent Director BinxianWei 53 2/5/2019 2/5/2019

Subsidiaries
Business Name Address City State/Province Country
Leading Biosciences, Inc. 5800 Armada Drive Carlsbad CA United States

Business Names
Business Name
CUR
Neuralstem Inc.
PALI
SNCA
Suzhou Neuralstem Biopharmaceutical Co., Ltd.
Townsgate Acquisition Sub 1, Inc.

General Information
Number of Employees: 9 (As of 12/31/2023)
Outstanding Shares: 851,401 (As of 4/8/2024)
Shareholders: 158
Stock Exchange: NASD
Federal Tax Id: 522007292
Fax Number: (302) 697-4597


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024